A MULTICENTER, PHASE 2, DOSE-ESCALATION/DOSE-EXPANSION STUDY OF TYRA-300 IN
CHILDREN WITH ACHONDROPLASIA WITH OPEN GROWTH PLATES: BEACH301
- Registry ID
- TYR300-201
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- TYRA BIOSCIENCES INC.
- Start date
- 2026-04-14
- Last update
- 2025-03-19
Conditions
Related clinical trials
- PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL, PRECEDED BY A SINGLE ASCENDING DOSE PORTION AND A PHASE 2 OPEN-LABEL PORTION, TO EVALUATE THE SAFETY AND EFFICACY OF ORAL INFIGRATINIB IN INFANTS AND YOUNG CHILDREN WITH ACHONDROPLASIA
- ATTACH: A PHASE 2, MULTICENTER, LONG-TERM, OPEN LABEL EXTENSION TRIAL EVALUATING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS DOSES OF TRANSCON CNP ADMINISTERED ONCE WEEKLY IN CHILDREN AND ADOLESCENTS WITH ACHONDROPLASIA
- PHASE 2, OPEN-LABEL, LONG-TERM, EXTENSION (OLE) STUDY OF INFIGRATINIB, AN FGFR 1-3-SELECTIVE TYROSINE KINASE INHIBITOR, IN CHILDREN WITH ACHONDROPLASIA: PROPEL OLE
View on source registry